TSLP rs10061459: Genetics of Eczema and Allergic Airway Disease
The genetic variant rs10061459 is an intergenic single nucleotide polymorphism situated upstream of the TSLP gene on chromosome 5. Research associates this variant with a modest statistical shift in the susceptibility to eczema-associated food allergy and allergic eosinophilic airway disease. Because it resides in a non-coding regulatory region, it reflects statistical risk modulation rather than a direct causative defect.
What each genotype means
Baseline risk profile
This genotype represents the common, non-risk version of this genetic variant. Research suggests that individuals with this profile do not carry the specific genetic association linked to increased susceptibility for eczema-associated food allergies or allergic eosinophilic airway disease. This is considered the baseline state in most populations.
Carried by approximately 49% of individuals of European ancestry.
Increased risk association
This genotype includes one copy of the variant associated with TSLP-related immune responses. Studies indicate that carriers of this genotype may have a statistically higher likelihood of developing eczema-associated food allergies or allergic eosinophilic airway disease compared to those without the variant. This association is based on population-level data and does not guarantee the development of these conditions.
Carried by approximately 42% of individuals of European ancestry.
Elevated risk association
This genotype includes two copies of the variant associated with TSLP-related immune responses. Research suggests that individuals with this profile may have a higher statistical risk for eczema-associated food allergies or allergic eosinophilic airway disease compared to those with one or no copies of the variant. As this is a complex trait, environmental factors also play a significant role in the actual manifestation of these conditions.
Carried by approximately 9% of individuals of European ancestry.
Genomic Context and Molecular Location
The single nucleotide polymorphism rs10061459 is located on chromosome 5q22.1, situated upstream of the human TSLP (thymic stromal lymphopoietin) gene according to the [NCBI dbSNP Database](https://www.ncbi.nlm.nih.gov/snp/rs10061459). This variant is an intergenic transition between cytosine and thymine alleles. Because it does not reside within an exon, it does not alter the primary amino acid sequence of any protein. Instead, it lies within a broader regulatory cluster in strong linkage disequilibrium with other non-coding variants that modulate transcriptional enhancers and promoters. Polymorphisms in this 5q22 locus frequently act as expression quantitative trait loci (eQTLs), influencing the rate at which adjacent immune-signaling transcripts are synthesized in epithelial tissues.
Biological Function of the TSLP Cytokine
The TSLP gene encodes thymic stromal lymphopoietin, an epithelial-derived cytokine that serves as a master regulator of type 2 (Th2) immune responses, as detailed in the [NCBI Gene Database](https://www.ncbi.nlm.nih.gov/gene/85480). Produced primarily by barrier cells in the skin, lungs, and gastrointestinal mucosa, TSLP is released upon physical damage, microbial encounter, or exposure to environmental allergens. Once secreted, it binds to a heterodimeric receptor complex on dendritic cells, basophils, and type 2 innate lymphoid cells (ILC2s), triggering the release of pro-inflammatory cytokines such as IL-4, IL-5, and IL-13. While essential for host barrier defense, excessive or prolonged local expression of TSLP can drive allergic inflammation, tissue eosinophilia, and the progression of the so-called 'allergic march' from atopic dermatitis to food allergies and asthma.
Evaluating Research and Association Strength
Studies documented in the [NHGRI-EBI GWAS Catalog](https://www.ebi.ac.uk/gwas/search?query=rs10061459) and [PubMed Literature](https://pubmed.ncbi.nlm.nih.gov/?term=rs10061459) highlight the 5q22.1 region as a recurring locus for atopic susceptibility, including atopic dermatitis, eosinophilic esophagitis, and childhood wheeze. Specifically, rs10061459 has been identified as a marker conferring altered risk for eczema-associated food allergies and allergic airway inflammation. However, current clinical databases classify the evidence for rs10061459 specifically as limited. Many recorded associations in this region stem from tight linkage with neighboring functional variants (such as rs3806932 or rs2289277) rather than rs10061459 acting independently. Furthermore, the magnitude of effect is modest, with odds ratios typically reflecting small relative changes in risk rather than large deterministic outcomes.
Population Distribution and Linkage Dynamics
The frequency of rs10061459 alleles displays noticeable variation across global populations. In populations of European ancestry, the minor allele frequency is approximately 0.30, meaning nearly half of individuals carry at least one copy of the alternative allele. In contrast, allele frequencies and underlying linkage disequilibrium patterns differ significantly in East Asian and African-descent populations. Because the LD architecture around the TSLP promoter is complex and ancestry-dependent, a marker that tracks closely with disease risk in one ancestral group may not have the same predictive power in another, emphasizing that statistical associations cannot be uniformly generalized across all backgrounds.
Interpreting Results: What You Can and Cannot Do
Discovering your genotype at rs10061459 provides insight into your inherited immune background, but it does not constitute a clinical diagnosis of eczema, food allergy, or asthma. Allergic diseases are classic complex traits shaped by dozens of genetic variants interacting with environmental triggers, including microbiome composition, allergen exposure, and skin barrier health. Carrying one or two risk alleles does not mean you will develop an allergy, nor does having a low-risk genotype guarantee immunity from atopic disorders. Genotypic findings should never guide dietary eliminations or medical regimens. Any decisions regarding allergy testing, asthma maintenance, or medication management must be evaluated by a physician or allergist based on clinical symptoms.
How common is this variant?
The minor allele frequency for rs10061459 is approximately 0.30 in populations of European ancestry, with varying frequencies and distinct linkage disequilibrium structures observed across other global ancestries.
Frequently asked questions
What is the link between rs10061459 and food allergies?
Research has linked rs10061459 to an increased statistical risk of food allergies that develop following or alongside childhood eczema. It sits near TSLP, a gene whose cytokine product helps coordinate allergic sensitization across damaged epithelial barriers.
Does having a risk allele mean I will definitely develop asthma or eczema?
No, it does not. Variant rs10061459 confers only a small shift in relative odds and is not deterministic. Many people carrying the risk allele never experience atopic symptoms, as environmental exposures and other genes play major roles.
Can testing this variant replace clinical allergy testing?
No. Genetic testing for non-coding variants like rs10061459 only measures statistical susceptibility, not actual immune reactivity. Diagnosis of allergies requires clinical assessment, skin prick tests, or specific IgE blood tests performed by a qualified healthcare professional.
Why is the evidence for rs10061459 described as limited?
While the 5q22 region containing TSLP is widely validated in allergic disease, rs10061459 specifically is often co-inherited with other nearby variants. It remains challenging for researchers to pinpoint whether rs10061459 directly changes gene activity or merely tags a nearby causal alteration.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs10061459?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in TSLP
A promoter variant regulating thymic stromal lymphopoietin expression, thereby controlling dendritic cell priming and eosinophilic allergic responses.
Upstream variant of thymic stromal lymphopoietin linked to elevated eosinophil activation and susceptibility to allergic disease.
An upstream promoter variant that alters thymic stromal lymphopoietin expression, mediating susceptibility to allergic rhinitis and childhood asthma.
Functional TSLP locus variant associated with circulating TSLP levels and predisposition to eosinophilic inflammation and asthma.
Upstream variant that alters thymic stromal lymphopoietin expression, increasing susceptibility to eosinophilic inflammation and food allergy.
Intergenic/promoter region SNP upstream of TSLP that strongly associates with eosinophilic esophagitis, asthma, atopic dermatitis, and allergic sensitization phenotypes.